Simultaneous integrated boost for adjuvant treatment of breast cancer- intensity modulated vs. conventional radiotherapy: The IMRT-MC2 trial
2011

IMRT-MC2 Trial: Comparing Two Radiotherapy Techniques for Breast Cancer

Sample size: 502 publication Evidence: moderate

Author Information

Author(s): Askoxylakis Vasileios, Jensen Alexandra D, Häfner Matthias F, Fetzner Leonie, Sterzing Florian, Heil Joerg, Sohn Christof, Hüsing Johannes, Tiefenbacher Uta, Wenz Frederik, Debus Jürgen, Hof Holger

Primary Institution: University of Heidelberg

Hypothesis

Is intensity modulated radiotherapy (IMRT) at least equivalent to conventional therapy in terms of cosmetic outcome and local control despite a reduced treatment duration?

Conclusion

The study aims to evaluate whether IMRT can provide similar or better outcomes compared to conventional radiotherapy while reducing treatment time.

Supporting Evidence

  • The study will evaluate cosmetic results and local control rates at 6 weeks and 2 years post-treatment.
  • Secondary objectives include overall survival, disease-free survival, and quality of life assessments.

Takeaway

This study is looking at two ways to give radiation to breast cancer patients to see if one way is better and faster than the other.

Methodology

A prospective, two-armed, multicenter, randomized phase-III trial comparing IMRT with integrated boost to conventional radiotherapy with consecutive boost.

Limitations

The study may have limitations related to patient selection and the generalizability of the results.

Participant Demographics

Patients aged >18 years and <70 years after breast conserving surgery, with specific risk factors for those aged ≥70.

Digital Object Identifier (DOI)

10.1186/1471-2407-11-249

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication